Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993, 260 (5112): 1317-1320. 10.1126/science.8493574.
Article
CAS
PubMed
Google Scholar
Friedrich CA: Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet. 2001, 10 (7): 763-767. 10.1093/hmg/10.7.763.
Article
CAS
PubMed
Google Scholar
Maher ER, Webster AR, Richards FM, Green JS, Crossey PA, Payne SJ, Moore AT: Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet. 1996, 33 (4): 328-332.
Article
CAS
PubMed
PubMed Central
Google Scholar
Neumann HP, Wiestler OD: Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet. 1991, 337 (8749): 1052-1054. 10.1016/0140-6736(91)91705-Y.
Article
CAS
PubMed
Google Scholar
Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R, Sampson J, Williams A, Ferguson-Smith MA, Morton N: Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991, 28 (7): 443-447.
Article
CAS
PubMed
PubMed Central
Google Scholar
Iliopoulos O, Ohh M, Kaelin WG: pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. PNAS. 1998, 95 (20): 11661-11666. 10.1073/pnas.95.20.11661.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schoenfeld A, Davidowitz EJ, Burk RD: A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. PNAS. 1998, 95 (15): 8817-8822. 10.1073/pnas.95.15.8817.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stebbins CE, Kaelin WG, Pavletich NP: Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 1999, 284 (5413): 455-461. 10.1126/science.284.5413.455.
Article
CAS
PubMed
Google Scholar
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999, 399 (6733): 271-275. 10.1038/20459.
Article
CAS
PubMed
Google Scholar
Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000, 2 (7): 423-427. 10.1038/35017054.
Article
CAS
PubMed
Google Scholar
Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, Klausner RD: The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. PNAS. 1997, 94 (6): 2156-2161. 10.1073/pnas.94.6.2156.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG: von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 2001, 10 (10): 1019-1027. 10.1093/hmg/10.10.1019.
Article
CAS
PubMed
Google Scholar
van der Harst E, de Krijger RR, Dinjens WN, Weeks LE, Bonjer HJ, Bruining HA, Lamberts SW, Koper JW: Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer. 1998, 77 (3): 337-340. 10.1002/(SICI)1097-0215(19980729)77:3<337::AID-IJC5>3.0.CO;2-P.
Article
CAS
PubMed
Google Scholar
Rothberg PG, Bradley JF, Baker DW, Huelsman KM: Is the P25L a "real" VHL mutation?. Mol Diagn. 2001, 6 (1): 49-54.
CAS
PubMed
Google Scholar
Pettman RK, Crowley A, Riddell C, Ludman MD: VHL P25L is not a pathogenic von Hippel-Lindau mutation: a family study. Mol Diagn Ther. 2006, 10 (4): 239-242.
Article
CAS
PubMed
Google Scholar
Patocs A, Karadi E, Toth M, Varga I, Szucs N, Balogh K, Majnik J, Glaz E, Racz K: Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre. Eur J Cancer Prev. 2004, 13 (5): 403-409. 10.1097/00008469-200410000-00008.
Article
CAS
PubMed
Google Scholar
O'Sullivan O, Suhre K, Abergel C, Higgins DG, Notredame C: 3Dcoffee : Combining protein sequences and structures within multiple sequence alignments. J Mol Biol. 2004, 340: 385-395. 10.1016/j.jmb.2004.04.058.
Article
PubMed
Google Scholar
Grantham R: Amino acid difference formula to help explain protein evaluation. Science. 1974, 185: 862-864. 10.1126/science.185.4154.862.
Article
CAS
PubMed
Google Scholar
Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A: Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitution as neutral. J Med Genet. 2006, 43 (4): 295-305. 10.1136/jmg.2005.033878.
Article
CAS
PubMed
Google Scholar
Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV: Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res. 2006, 34 (5): 1317-1325. 10.1093/nar/gkj518.
Article
CAS
PubMed
PubMed Central
Google Scholar
Website title. [http://agvgd.iarc.fr]
Guex N, Peitsch MC: SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997, 18 (15): 2714-2723. 10.1002/elps.1150181505.
Article
CAS
PubMed
Google Scholar
Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, et al: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat. 1995, 5 (1): 66-75. 10.1002/humu.1380050109.
Article
CAS
PubMed
Google Scholar
Assadi F, Brackbill EL: Bilateral pheochromocytomas and congenital anomalies associated with a de novo germline mutation in the von Hippel-Lindau gene. Am J Kidney Dis. 2003, 41 (1): E3-10.1053/ajkd.2003.50021.
Article
PubMed
Google Scholar
Woodward ER, Eng C, McMahon R, Voutilainen R, Affara NA, Ponder BA, Maher ER: Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet. 1997, 6 (7): 1051-1056. 10.1093/hmg/6.7.1051.
Article
CAS
PubMed
Google Scholar
Glavac D, Neumann HP, Wittke C, Jaenig H, Masek O, Streicher T, Pausch F, Engelhardt D, Plate KH, Hofler H, et al: Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum Genet. 1996, 98 (3): 271-280. 10.1007/s004390050206.
Article
CAS
PubMed
Google Scholar
Dollfus H, Massin P, Taupin P, Nemeth C, Amara S, Giraud S, Beroud C, Dureau P, Gaudric A, Landais P, et al: Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophth Vis Sci. 2002, 43 (9): 3067-3074.
Google Scholar
Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, Zbar B, Affara NA, Ferguson-Smith MA, et al: Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet. 1994, 3 (8): 1303-1308. 10.1093/hmg/3.8.1303.
Article
CAS
PubMed
Google Scholar
Bluyssen HA, Lolkema MP, van Beest M, Boone M, Snijckers CM, Los M, Gebbink MF, Braam B, Holstege FC, Giles RH, et al: Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett. 2004, 556 (1–3): 137-142. 10.1016/S0014-5793(03)01392-9.
Article
CAS
PubMed
Google Scholar
Miller F, Kentsis A, Osman R, Pan ZQ: Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex. J Biol Chem. 2005, 280 (9): 7985-7996. 10.1074/jbc.M413160200.
Article
CAS
PubMed
Google Scholar
Guerois R, Nielsen JE, Serrano L: Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol. 2002, 320 (2): 369-387. 10.1016/S0022-2836(02)00442-4.
Article
CAS
PubMed
Google Scholar
Ruiz-Llorente S, Bravo J, Cebrian A, Cascon A, Pollan M, Telleria D, Leton R, Urioste M, Rodriguez-Lopez R, de Campos JM, et al: Genetic characterization and structural analysis of VHL Spanish families to define genotype-phenotype correlations. Hum Mutat. 2004, 23 (2): 160-169. 10.1002/humu.10309.
Article
CAS
PubMed
Google Scholar
Cybulski C, Krzystolik K, Murgia A, Gorski B, Debniak T, Jakubowska A, Martella M, Kurzawski G, Prost M, Kojder I, et al: Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. J Med Genet. 2002, 39 (7): E38-10.1136/jmg.39.7.e38.
Article
CAS
PubMed
PubMed Central
Google Scholar